ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presented a mixed outlook. Financial metrics were not fully disclosed, and management's responses in the Q&A lacked clarity, raising uncertainties. However, the company’s strategic initiatives, including advancing key drug candidates and a solid financial runway, provide a stable foundation. No strong catalysts or detractors were evident, suggesting a neutral stock price movement over the next two weeks.
Key Financial Performance
Median Duration of Response (DOR) 20 months, a Percentage Change year-over-year not mentioned. The reason for the change is the durability observed with an IO mechanism.
Median Progression-Free Survival (PFS) 22 months, a Percentage Change year-over-year not mentioned. The reason for the change is the improved benchmarks due to the efficacy of the treatment.
Objective Response Rate (ORR) 33% for all 24 patients, 60% for 10 patients with centrally confirmed HER2-positive breast cancer, and 100% for 5 patients with CD47 overexpression. The reasons for the changes are the targeted therapy's efficacy and the use of biomarkers like CD47 expression.
Median PFS for CD47 High Patients 22 months, compared to 3.4 months for CD47 Low Patients. The reason for the change is the targeted efficacy of the treatment in CD47 high patients.
Median DOR for CD47 High Patients 20.2 months, compared to lower durations for CD47 Low Patients. The reason for the change is the targeted efficacy of the treatment in CD47 high patients.
Median PFS in ASPEN-06 HER2-positive Gastric Study 18.4 months for CD47 high patients, with a hazard ratio of 0.39. The reason for the change is the targeted efficacy of the treatment in CD47 high patients.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Evorpacept (Evo): Demonstrated significant potential in HER2-positive metastatic breast cancer, especially in patients with high CD47 expression. Data from trials showed a 100% response rate in HER2-positive and CD47-high patients, with a median duration of response of 20 months and progression-free survival (PFS) of 22 months. Ongoing ASPEN-09 Phase II trial is progressing well.
ALX2004: A novel EGFR-targeted ADC with potential to be first-in-class. Designed to address challenges in targeting EGFR with ADCs. Dose escalation is progressing well, with initial safety data expected in the second half of 2026.
HER2-positive and CD47-high patient market: Estimated 20,000 addressable patients in the US, Europe, and Japan, representing a $2 billion to $4 billion market opportunity.
Clinical Development Progress: Both Evorpacept and ALX2004 programs are on track, with significant data readouts expected in the next 12-18 months.
Leadership Strengthening: Jeff Knight joined as Chief Development and Chief Operating Officer, enhancing the leadership team.
Financing: Secured strong financing in February 2026, strengthening the balance sheet to support key milestones.
Targeted Oncology Approach: Focus on leveraging CD47 as a predictive biomarker to optimize patient selection and enhance treatment efficacy.
Pipeline Expansion: Advancing two novel cancer treatments with the aim of achieving registrational study readiness by the end of 2027.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market competition and unmet needs: The company faces challenges in addressing unmet needs in HER2-positive breast cancer treatment, particularly for patients post-T-DXd treatment, where progression-free survival rates are low. Competitive pressures exist with other HER2-targeted therapies in development.
Regulatory and clinical trial risks: The success of evorpacept and ALX2004 depends on ongoing clinical trials, including ASPEN-09 and Phase I trials. Delays or failures in achieving safety and efficacy milestones could impact strategic objectives.
Biomarker-driven approach: The reliance on CD47 as a predictive biomarker for evorpacept's efficacy introduces risks if the biomarker fails to consistently predict patient outcomes or if testing methods are not standardized.
Supply chain and operational execution: The company must ensure smooth enrollment and execution of clinical trials globally, which could be impacted by operational inefficiencies or external disruptions.
Financial sustainability: Although recent financing strengthens the balance sheet, the company remains dependent on achieving key milestones to secure further funding and sustain operations.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Evorpacept Phase II Breast Trial: The trial is progressing well with strong global enrollment and increasing site enthusiasm. Clinical timelines remain on track, with an expected readout of 80 patients by mid-2027. The goal is to have the program ready for registrational studies by the end of 2027.
ALX2004 Phase I Trial: The trial is progressing well with enrollment and dose escalation ramping up. Initial safety readout is expected in the second half of 2026. The program aims to be ready for registrational studies by the end of 2027.
Evorpacept and Zanidatamab Combination: Promising antitumor activity observed in heavily pretreated HER2-positive metastatic breast cancer patients. Greater efficacy seen in patients with centrally confirmed HER2-positive disease and high CD47 expression. Interim top-line data from approximately 80 patients expected by mid-2027.
Market Opportunity for Evorpacept: The company estimates a market opportunity of $2 billion to $4 billion for HER2-positive and CD47-overexpressing patients in the U.S., Europe, and Japan.
ALX2004 Development: The EGFR-targeted ADC is progressing well in dose escalation. Initial safety data is expected in the second half of 2026, with the aim to advance to registrational studies by the end of 2027.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What would be compelling results for the upcoming interim data readout in mid-2027 from the Phase II ASTENBreast study in terms of ORR, DOR, and mPFS?
A:Management expects a 30% ORR (doubling the expected 15% without evorpacept) and a DOR of 6 months or more. However, mPFS data might be too immature to report by mid-2027.
Q:How does management plan to use the drug in the clinical setting if approved, and will CD47 expression testing be required?
A:Management is exploring the role of CD47 expression as a predictive marker. If validated, it could be developed as a companion diagnostic. However, there is currently insufficient data to make definitive statements.
Q:What is the population in ASPEN-09, and how does it compare to the patients from the update?
A:The ASPEN-09 study focuses on a late-line breast cancer population, similar to the cohort in the update, with patients having received an average of 5 prior lines of HER2-directed therapy.
Q:Does the 20,000 CD47 high post-HER2 patient estimate assume greater than 20% CD47 expression?
A:Management did not provide a direct answer but mentioned that expression profiles vary across tumor types and that ASPEN-09 will help optimize the cut point for CD47 expression.
Q:What is the latest on companion diagnostic development, and does the CD47 biomarker strategy impact statistical powering for ASPEN-09?
A:The Ventana Laboratory is developing a companion diagnostic, aiming for availability by the Phase III trial. The CD47 biomarker strategy allows for a more targeted Phase III trial, but ASPEN-09 is not powered for 100% ORR.
Q:How does HER2 amplification by ctDNA and FISH translate into HER2 positivity in IHC?
A:There is good concordance between HER2 amplification by FISH and ctDNA, but differences may arise due to testing older tissue or using fresh biopsy samples. Central HER2 amplification correlates well with ctDNA.
Q:Are half of HER2-positive patients in ASPEN-09 CD47 high, and are tissue adequacy and turnaround time gating factors for enrollment?
A:Management did not disclose CD47 prevalence rates but stated that tissue adequacy and turnaround time are not gating factors for ASPEN-09 enrollment.
Q:What are the nuances of the two CD47 high cutoffs used in the Phase Ib/II breast cancer study and ASPEN-09?
A:The cutoffs differ due to variations in expression profiles across tumor types. ASPEN-09 will optimize the cutoff, and the current methods involve cumulative total membrane staining scores.
Q:Is accelerated approval based on ASPEN-09 a possibility, or is a Phase III trial required?
A:Accelerated approval is unlikely due to the high bar for single-arm trials with combination agents and retrospective companion diagnostics. A Phase III trial is the base case, but extraordinary response rates could prompt discussions with the FDA.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the CD47 high cutoff for the 20,000 patient estimate and did not disclose CD47 prevalence rates in ASPEN-09. They also used vague language regarding the potential for accelerated approval, emphasizing the high bar but leaving the possibility open depending on response rates.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ALX potential
ASPEN Phase
CD overexpressing
Cancer Center
Center University
Clinical Research
DXd
Evo ALX
Fred Hutch
Hutch Cancer
II study
Ib II
Phase Ib
Slide consistency
University Washington
analysis Phase
antibody drug
antibody signal
area
combination evorpacept
enrollment
evorpacept zanidatamab
expression patient
graph
kilogram
left
market
milligram
month PFS
month patient
patient breast
patient disease
patient response
progression survival
rate patient
row
side
stage
study PFS
subset
tumor CD
ALXO Transcript
ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript
Unknown5-9
The earnings call presented a mixed outlook. Financial metrics were not fully disclosed, and management's responses in the Q&A lacked clarity, raising uncertainties. However, the company’s strategic initiatives, including advancing key drug candidates and a solid financial runway, provide a stable foundation. No strong catalysts or detractors were evident, suggesting a neutral stock price movement over the next two weeks.
ALX Oncology Holdings Inc. (ALXO) Q4 2025 Earnings Call Transcript
Unknown2-27
The earnings call presents a mixed picture. Financial performance shows a decrease in net loss, but reliance on recent financing raises sustainability concerns. Product updates are promising, with trial expansions and positive biomarker feedback, yet delays in data release and manufacturing challenges persist. The Q&A reveals enthusiasm but also uncertainties in trial outcomes and biomarker validation. The absence of a market cap limits prediction precision, but the overall cautious outlook and mixed signals suggest a neutral stock price movement in the short term.
ALX Oncology Holdings Inc. (ALXO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-15
ALX Oncology Holdings Inc. (ALXO) Q3 2025 Earnings Call Transcript
Positive11-7
The company's strategic focus on biomarker-driven approaches and strong clinical trial results in HER2-positive cancers indicate promising developments. The extension of the cash runway into 2027 and the Sanofi collaboration further enhance the outlook. Despite some uncertainties in execution and supply chain risks, the positive clinical data and strategic partnerships suggest a positive market reaction.
ALXO Slides
ALXO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
